

Salbutamol

FORM 2.5mg/2.5ml nebuliser solution
** Special Care required – other strengths available**

INDICATION Treatment of reversible airways disease
Treatment of hyperkalaemia (IV route preferred)

DOSE RANGE

1. Treatment of reversible airways disease

AGE	DOSE	FREQUENCY	ROUTE
Birth – 6 months	2.5mg/dose	4 – 6 hourly	Nebulised

2. Treatment of hyperkalaemia

AGE	DOSE	FREQUENCY	ROUTE
Birth – 6 months	2.5-5mg	Single dose Repeat as necessary	Nebulised

NOTE Nebulised therapy may be ineffective in children under 18 months

CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS

- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

FURTHER INFORMATION Nebulised salbutamol has been associated with mild (but occasionally severe) paradoxical bronchospasm and transient worsening of oxygen saturation

LICENSED STATUS Not licensed for hyperkalaemia

LINKS [BNF for Children](#): / [Electronic Medicines Compendium](#)

APPLICABLE POLICIES [West of Scotland Neonatal Guidelines](#):

Consult local policy if applicable

Document Number:	002	Supersedes:	001
Prepared by:	WoS NeoPharm Group	Checked by	Peter Mulholland
Date prepared	October 2016	Date updated	October 2021
Updated by	Peter Mulholland	Review Date	October 2024

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications.
This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.